Movement Alert｜3SBio Falls 5.24% in Regular Trading, Biotechnology Sector Broadly Under Pressure

Market Focus07-07

On July 7, 3SBio fell 5.24% in regular trading, trading at HK$18.44/share, with turnover of HK$387 million. The decline came amid broad-based selling pressure across the biotechnology sector.

Within the Biotechnology sector where 3SBio belongs, individual stocks were broadly weaker. Among peers, Remegen fell 6.6%, Akeso fell 4.37%, Innovent Bio fell 3.48%, BeiGene fell 2.83%, and SKB Bio fell 2.2%. Earlier sector analysis from CITIC Construction Investment noted that the biopharmaceutical sector had been tracking the overall pharmaceutical industry pullback, likely related to capital and funding rotation factors.

Notably, 3SBio had risen 7.77% in the prior session on July 3, supported by innovative drug payment reform catalysts and a series of share buybacks totaling approximately 8.52 million shares in June. The current pullback partially reverses those recent gains.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1181825711?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-07 13:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1181825711","market":"hk","top_or_hot":-1,"title":"Movement Alert｜3SBio Falls 5.24% in Regular Trading, Biotechnology Sector Broadly Under Pressure","media":"Market Focus","content":"<p><p>On July 7, 3SBio fell 5.24% in regular trading, trading at HK$18.44/share, with turnover of HK$387 million. The decline came amid broad-based selling pressure across the biotechnology sector.</p><p>Within the Biotechnology sector where 3SBio belongs, individual stocks were broadly weaker. Among peers, Remegen fell 6.6%, Akeso fell 4.37%, Innovent Bio fell 3.48%, BeiGene fell 2.83%, and SKB Bio fell 2.2%. Earlier sector analysis from CITIC Construction Investment noted that the biopharmaceutical sector had been tracking the overall pharmaceutical industry pullback, likely related to capital and funding rotation factors.</p><p>Notably, 3SBio had risen 7.77% in the prior session on July 3, supported by innovative drug payment reform catalysts and a series of share buybacks totaling approximately 8.52 million shares in June. The current pullback partially reverses those recent gains.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜3SBio Falls 5.24% in Regular Trading, Biotechnology Sector Broadly Under Pressure</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜3SBio Falls 5.24% in Regular Trading, Biotechnology Sector Broadly Under Pressure\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-07 13:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 7, 3SBio fell 5.24% in regular trading, trading at HK$18.44/share, with turnover of HK$387 million. The decline came amid broad-based selling pressure across the biotechnology sector.</p><p>Within the Biotechnology sector where 3SBio belongs, individual stocks were broadly weaker. Among peers, Remegen fell 6.6%, Akeso fell 4.37%, Innovent Bio fell 3.48%, BeiGene fell 2.83%, and SKB Bio fell 2.2%. Earlier sector analysis from CITIC Construction Investment noted that the biopharmaceutical sector had been tracking the overall pharmaceutical industry pullback, likely related to capital and funding rotation factors.</p><p>Notably, 3SBio had risen 7.77% in the prior session on July 3, supported by innovative drug payment reform catalysts and a series of share buybacks totaling approximately 8.52 million shares in June. The current pullback partially reverses those recent gains.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01530","symbol_name":"三生制药","start_time":0,"source_url":"","article_id":"1181825711","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1181825711","pubTimestamp":1783403856,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 7, 3SBio fell 5.24% in regular trading, trading at HK$18.44/share, with turnover of HK$387 million. The decline came amid broad-based selling pressure across the biotechnology sector.Within...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01530":"三生制药"},"translate_title":"动向提示|三生制药常规交易跌5.24%生物科技板块普遍承压","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01530":1},"content_text":"On July 7, 3SBio fell 5.24% in regular trading, trading at HK$18.44/share, with turnover of HK$387 million. The decline came amid broad-based selling pressure across the biotechnology sector.Within the Biotechnology sector where 3SBio belongs, individual stocks were broadly weaker. Among peers, Remegen fell 6.6%, Akeso fell 4.37%, Innovent Bio fell 3.48%, BeiGene fell 2.83%, and SKB Bio fell 2.2%. Earlier sector analysis from CITIC Construction Investment noted that the biopharmaceutical sector had been tracking the overall pharmaceutical industry pullback, likely related to capital and funding rotation factors.Notably, 3SBio had risen 7.77% in the prior session on July 3, supported by innovative drug payment reform catalysts and a series of share buybacks totaling approximately 8.52 million shares in June. The current pullback partially reverses those recent gains.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1181825711","isCrawlerRequest":true}